GATA3 rs962993: Genetic Risk for Allergic Sensitization
The genetic variant rs962993 is a single-nucleotide polymorphism located within an intronic region of the GATA3 gene on chromosome 10. Large-scale genome-wide association studies have identified this variant as being associated with self-reported allergy susceptibility and allergic sensitization. Because GATA3 is a master regulator of T helper 2 immune cell differentiation, variation at this locus offers valuable insight into the biological pathways governing atopic conditions.
What each genotype means
| Genotype | What the research suggests | Reading |
|---|---|---|
| CC | The CC genotype represents two copies of the major cytosine allele. Individuals with this genotype carry the baseline reference profile at this marker, typically corresponding to average population odds for allergic sensitization. It does not confer immunity to allergies, as environmental and polygenic influences remain dominant. | Informational |
| CT | The CT genotype indicates heterozygosity, possessing one copy of the cytosine allele and one copy of the thymine allele. In population-scale association studies, carrying one copy of the risk allele is linked to a subtle, incremental change in self-reported allergy and allergic sensitization risk. This slight elevation does not guarantee the development of allergic symptoms. | Higher attention |
| TT | The TT genotype represents homozygosity for the thymine allele. Individuals with this genotype carry two copies of the variant associated with allergic sensitization in large GWAS datasets. While statistical risk is slightly higher relative to baseline, clinical atopic status is determined by extensive immune, lifestyle, and environmental interactions. | Higher attention |
Genomic Location and Variant Characteristics
The single-nucleotide polymorphism rs962993 is located on the short arm of chromosome 10 (10p14) within the genomic boundaries of the GATA3 gene. It represents a common non-coding variation, specifically residing in an intronic segment where it does not directly alter the amino acid sequence of the resulting protein. The primary alleles identified in human populations are cytosine (C) and thymine (T). As an intronic marker, rs962993 is hypothesized to function as a regulatory variant or to serve as a proxy in linkage disequilibrium with other non-coding variants that influence gene transcription, chromatin accessibility, or RNA splicing efficiency rather than directly disrupting the coding structure.
The Biological Role of GATA3
The GATA3 gene encodes GATA-binding protein 3, a dual zinc-finger transcription factor that plays an indispensable role in the development and functional commitment of the adaptive immune system. GATA-3 is widely recognized as the master transcriptional regulator of T helper type 2 (Th2) cell differentiation. In naive CD4+ T cells, the activation of GATA3 orchestrates the expression of hallmark type 2 cytokines, notably interleukin-4 (IL-4), interleukin-5 (IL-5), and interleukin-13 (IL-13). These signaling molecules drive class-switching in B cells toward immunoglobulin E (IgE) production, eosinophil recruitment, and mucus hypersecretion. Because these pathways are central to allergic inflammation, subtle regulatory shifts in GATA3 expression can shift the balance between immune tolerance and atopic reactivity.
Research Findings and Evidence Strength
Genome-wide association studies (GWAS), including landmark analyses of allergic conditions across large population cohorts, have repeatedly linked the GATA3 locus to allergic rhinitis, broad self-reported allergies, and allergic sensitization. In studies assessing self-reported allergy phenotypes and allergic sensitization assays, rs962993 has emerged as an index or tagging SNP demonstrating statistically robust association signals. Despite this statistical strength, the scientific evidence regarding individual diagnostic impact remains classified as limited. Each risk allele imparts only a modest incremental change in odds, reflecting the polygenic architecture of allergic disorders where hundreds of loci interact with environmental allergens. The variant is an indicator of baseline immune tendency rather than a direct causative switch.
Population Distribution and Ancestry Trends
The minor allele frequency for rs962993 is approximately 27% across global reference populations in resources like the 1000 Genomes Project and gnomAD. However, the prevalence of the C and T alleles varies among distinct ancestral backgrounds. It is observed as a frequent polymorphism in European, East Asian, and other continental groups, though exact allele proportions fluctuate between cohorts. Because much of the initial genome-wide mapping for self-reported allergic disease was conducted in predominantly European-ancestry cohorts, the specific effect sizes in understudied populations remain an area of ongoing active research.
Translating Genetic Findings Responsibly
Learning your rs962993 genotype does not constitute a clinical diagnosis of allergic rhinitis, asthma, or any specific environmental allergy. Carrying one or two copies of an allergy-associated allele slightly nudges population-level susceptibility but cannot predict whether an individual will develop symptoms, which specific allergens might trigger a reaction, or how severe an allergic episode could be. Environmental exposures, lifestyle, microbiome factors, and childhood infections interact heavily with genetic predisposition. Genetic data should never be used to initiate, alter, or discontinue allergy medications or immunotherapies without explicit guidance and diagnostic testing from a qualified allergist or primary care provider.
How common is this variant?
The global minor allele frequency of rs962993 is approximately 27% according to data from gnomAD and the 1000 Genomes Project, though exact allele frequencies vary across ancestral groups.
Frequently asked questions
Does having the rs962993 risk variant mean I will definitely develop allergies?
No. Allergic conditions are complex, multifactorial traits influenced by hundreds of genetic variants alongside environmental factors such as pollen levels, air quality, and childhood allergen exposure. Carrying this variant only slightly shifts statistical susceptibility across a population.
Can rs962993 testing tell me which specific allergens I react to?
No, this genetic marker does not identify individual allergen triggers such as cat dander, grass pollen, or specific foods. Determining personal allergen sensitivities requires clinical evaluation, such as skin-prick testing or allergen-specific serum IgE measurements directed by a medical professional.
How does the GATA3 gene influence allergic reactions?
GATA3 encodes a key transcription factor that instructs naive immune cells to mature into Th2 cells. These Th2 cells produce cytokines that trigger IgE antibody production and mucosal inflammation, both of which are core processes in allergic responses.
Should I change my allergy medications based on my rs962993 genotype?
You should not alter, stop, or start any medications based on rs962993 results. This variant is not an established pharmacogenetic biomarker for dosing or drug efficacy. Any adjustments to allergy therapies or antihistamines must be discussed with your physician or pharmacist.
Sources & further reading
Educational information only, last refreshed 9/7/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs962993?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29